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Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of 
life, and associated supportive care: a cross-sectional survey 
 
Purpose: To identify the treatment-associated problems that most impact on patients undergoing 
cancer chemotherapy, how problems relate to experiences of supportive care and variations in 
experience between cancer treatment centres.    
Methods: A survey administered to patients at six cancer centres in England explored variations of 
prevalence of 17 cancer chemotherapy-associated problems and associated supportive care. 
Problem items were identified as the most frequently experienced and severe when experienced in 
a scoping and consensus exercise. A health-related quality of life (HRQoL) measure, the EQ5D, was 
included to measure impact of problems.  
Results: 363 completed questionnaires were returned (response rate 43%, median 61%). The most 
prevalent problem was ‘tiredness/fatigued’ (90%), followed by ‘changes in taste & smell’ (69%) and 
‘difficulty managing everyday tasks’ (61%). Significant variations in problem prevalence existed 
between centres and some common problems were rarely reported in the literature. Regression 
analysis found almost all problems were significantly associated with HRQoL, with social/emotional 
problems having as much impact on HRQoL as physical/psychological side-effects of treatment. 
Greatest effect size was for ‘difficulty managing everyday tasks’. Respondents reported significant 
variations in supportive care between centres, with more supportive care received for 
physical/psychological problems than for social/emotional problems. Findings indicated patients 
who received increased supportive care experienced less severe problems.    
Conclusion: The most common and distressing chemotherapy-associated problems were identified. 
These problems are mitigated by quality supportive care. Routine measurement and monitoring of 
problem items and supportive care are warranted to facilitate benchmarking and service 
improvements both within and between cancer centres. 
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INTRODUCTION 
More than 165,000 patients currently receive chemotherapy each year[1], which is increasingly 
administered in ambulatory outpatient rather than inpatient care settings[2,3,4,5,6]. Despite 
increasingly aggressive regimens, few patients in the UK will require hospitalisation[7]. Nevertheless, 
patients undergoing chemotherapy experience substantial levels of distress across a wide range of 
physical and psycho-social problems[8,9,10]. The shift to outpatient chemotherapy provision means 
patients and their families are likely to encounter problems outside the hospital setting, without 
immediate access to professional health advice. Moreover, patients will sometimes abandon 
chemotherapy prematurely as a result of treatment-associated problems, despite potentially life-
threatening consequences[10]. 
Managing the supportive care needs of cancer patients involves helping them and their family cope 
with problems associated with cancer and treatment[11], and is fundamental to delivering high 
quality, person-centred care[12,13,14]. To ensure quality supportive care for patients undergoing 
chemotherapy, we need to understand the problems they experience and which have greatest 
impact. A scoping review by this research team identified studies that reported the prevalence of a 
range of chemotherapy-associated problems[8]. These studies have usually been limited to physical 
and psychological symptoms such as fatigue, nausea or depression. While the impact of 
chemotherapy on social and emotional issues have previously been explored, including personal 
relationships, work and finances[15,16,17], very few studies have reported the prevalence of such 
problems. Nevertheless, where prevalence was reported, social and emotional problems were found 
to be as prevalent as physical side-effects[18,19]. Recognition of the full range of the most common 
chemotherapy-associated problems would allow a more patient-centred and holistic approach to 
supportive care.  
In our previous research, variations in rate of both problems and support experienced by patients 
were identified across ambulatory chemotherapy units[9,20]. For example, prevalence of moderate 
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to severe nausea ranged between 24%-73% at different sites, while those reportedly not receiving 
practical advice for managing their symptoms ranged from 1%-13%[9]. Such wide variations 
satisfaction and experience with cancer care reflects previous international 
evidence[21,22,23,24,25]. 
In order to benchmark and improve health service quality and outcomes between units and over 
time, suitable measurement tools are required. Patient-reported outcome measures (PROMs) and 
experience measures (PREMs) are increasingly recognised internationally as an important tool for 
such situations[26]. Concern to address variations in care quality in the UK has led to the first 
national PREM initiative to benchmark and monitor patient experience of care. The national Cancer 
Patient Experience Survey (CPES) now regularly explores care experienced by cancer patients in 
England and has identified improvements over time[27]. However, limitations would exist for any 
national PROM/PREM survey designed for use across different treatment types and care sectors, and 
only four CPES survey questions specifically ask about care as a day patient or outpatient. 
Furthermore the results do not give any specific indication of the problems that patients experience 
and whether services are responding effectively to provide support. Such data is therefore of limited 
use when seeking to address the specific experience of patients in an ambulatory chemotherapy 
environment and to improve patient reported outcomes and quality of supportive care received. 
This study therefore aimed to identify the most common problems experienced by people with 
cancer receiving ambulatory chemotherapy and which had greatest impact, and to explore how 
these problems relate to peoples’ experiences of supportive care.  
MATERIAL AND METHODS 
Development of questionnaire 
Invited clinicians (n=32) at six participating cancer centres, together with cancer survivors of a range 
of tumour sites (n=41) recruited via ‘Cancer Voices Online’, formed a reference panel to aid selection 
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of items for the questionnaire via an online survey. Panel members were presented with a list of 27 
common problems identified from a systematic review[8], supplemented by common problems 
identified in our previous study[9,20]. All panel members were asked to assess from their experience 
as patients or clinicians the frequency of each problem and how often these problems were severe. 
Panel members were asked to identify up to three additional problems they thought were at least as 
common as those on the list and rate them in terms of frequency/severity. Items were ranked in two 
lists, frequency and severity, with items that appeared in the top ten of either list selected for 
inclusion in the final questionnaire. The top ten only were selected from each list to ensure a 
manageable number of items. There was some overlap between these two lists, with items 
appearing on both giving a final total of 17 items for the questionnaire. Panel members were then 
requested to assess their experience of supportive care to manage both physical and psychological 
problems (i.e. ‘losing your hair’ or ‘low in mood’ and social and emotional problems ‘i.e. difficulties 
in relationships with family and friends’ and ‘financial worries’). (always/usually/ occasionally/never). 
We also included three questions for review regarding preparation for what problems to expect and 
who to contact in emergencies. The draft questionnaire comprised the final list of problems, asking 
respondents about severity (not at all/mild/moderate/severe), questions about levels of supportive 
care and socio-demographic characteristics. Respondents were asked to report any problems they 
were experiencing in addition to the 17 listed in the questionnaire, and their severity 
(mild/moderate/severe).  An existing validated health-related quality of life (HRQoL) measure, the 
EQ5D[28], was also included. HRQoL is a multi-dimensional concept that includes physical, mental, 
emotional and social functioning, and focuses on the impact health status has on quality of life. The 
EQ5D measure comprises five domains from which a single summary score can be calculated: 
mobility; self-care; usual activities; pain/discomfort; anxiety/depression. The EQ5D was used to 
validate the included problem items by measuring their association with HRQoL. The 2-page, 4-side 
instrument underwent cognitive testing with a small number (n=12) of patients attending 
chemotherapy outreach services at two locations. Slight amendments were subsequently made to 
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the wording of the questionnaire. The instrument took patients approximately 15 minutes to 
complete. 
Setting and participants 
The finalised paper-based questionnaire was distributed to chemotherapy patients at six cancer 
centres across England. Our aims were to assess prevalence of problems and variations in 
prevalence and supportive care between centres, to assess acceptability and feasibility of use (e.g. 
by monitoring rates of response and missing data) and to conduct preliminary validation by 
measuring associations with the EQ5D.  
National Health Service (NHS) cancer treatment and supportive care services in the UK are free at 
the point of use, should be of consistent quality across the country and be designed around the 
needs of patients[13,29]. Supportive care services available include specialist nurses (Clinical Nurse 
Specialist, Nurse Consultants and Nurse Practitioners) although provision varies by centre and 
tumour site, with variation in these services associated with known variation in patient 
experience[30]. All six collaborating centres were NHS ambulatory cancer units that provided similar 
chemotherapy treatment pathways to patients with a range of primary cancer sites, though they 
varied in size from regional cancer centres to local hospital sites.   
Each centre agreed to invite 120 individuals who attended outpatients and fulfilled the following 
inclusion criteria, to complete a questionnaire: 
 Patients receiving ‘curative’ chemotherapy treatment only; 
 Patients receiving chemotherapy for any primary cancer diagnosis; 
 Patients receiving any cycle of chemotherapy treatment, except their first cycle.  
Staff sickness at centre 4 during the data collection period, including the nurse co-ordinating the 
study, meant only 64 outpatients were invited to complete the questionnaire at that site. Any 
questionnaires not administered were returned to the research team.  
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Data collection occurred between 20/11/2013 and 03/01/2014. Patients were encouraged to return 
the completed questionnaires to a collection box in each unit. However, some patients preferred to 
complete questionnaires at home and pre-paid envelopes were provided for these to be returned.  
ETHICS 
This work was conducted as a service evaluation, assessed as not requiring approval by the National 
Research Ethics Service. Local approvals were gained from R&D departments at participating cancer 
treatment centres. All participants were given full information about the project and consent was 
indicated by completion and return of questionnaires. All questionnaires were anonymous. 
ANALYSIS 
Data were entered into Stata v13.1. Descriptive statistics and χ2 tests were used to explore 
demographic data, reported frequency and severity of problems and experience of supportive care. 
Each participant’s single index EQ5D scores was calculated (summarising five domains: mobility; self-
care; usual activities; pain/discomfort; anxiety/depression). Univariate and multivariate linear 
regression analysis explored associations and patterns between reported severity of problem items, 
summary EQ5D scores and supportive care received. All regression analyses were controlled for age, 
gender and treating cancer centre.   
RESULTS 
Overall survey response rate was 43% (n=363), with a range of 20%–78% between sites (median 61%) 
(Table 3). Respondents included more women than men, and breast was the most frequent tumour 
site (24.8%), followed by bowel, lung and gynaecological. The highest proportions of respondents 
were undergoing their seventh or third chemotherapy cycles. Questionnaires were completed in 
their entirety by 70.5% (n=256/363) of participants; a further 87 had either one or two missing items, 
indicating question items were acceptable to participants. Analysis of variations in response 
between centres found significant differences in gender (χ2(5)=17.2, p=.004) and tumour type 
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(χ2(60)=138.2, p=<.001), but no significant differences between age groups of respondents or the 
cycle of chemotherapy they were receiving.   
Problem prevalence and severity 
The problem most frequently reported was ‘tiredness, fatigued or lacked energy’, with 90% of 
respondents reporting it represented a mild, moderate or severe problem for them (Table 1). Ten of 
the seventeen problems were experienced by more than 50% of respondents. Although ‘losing your 
hair’ was experienced by less than half of respondents (46%), it was nevertheless the condition that 
the highest proportion of those who did experience it reported it to be ‘severe’ (13%). Least 
frequently reported were ‘difficulties in relationships with family or friends’, although it was still a 
problem for almost a fifth (19%) of participants. Significant differences in reported prevalence were 
found to exist between centres for seven problems: ‘tired, fatigued or lacked energy’ (χ2(15)=29.300, 
p=.015); ‘trouble sleeping’ (χ2(15)=30.600, p=.010); ‘feeling sick (queasy/nausea)’ (χ2(15)=26.681, 
p=.031); ‘losing your hair’ (χ2(15)=32.213, p=.006); ‘low mood’ (χ2(15)=36.138, p=.006), ‘financial 
worries’ (χ2(15)=26.680, p=.031) and ‘diarrhoea’ (χ2(15)=25.667, p=.042). In total, 80 respondents 
provided 105 additional problems, almost all of which could be categorised within our working 
typology, with the most often reported additional problems being ‘tingling/numbness’ (n=16), ‘pain’ 
(n=14) and ‘skin problems’ (n=11). Nevertheless, all additional problems were substantially less 
frequently reported than items already listed in the questionnaire.  
Association of problem items with HRQoL 
Individual summative EQ5D scores incorporated the full range of those possible with 24 individuals 
indicating their health was the best they could imagine (100) and one indicating it was the worst (0). 
The median EQ5D summative score was 75 (mean 72), with the interquartile range (IQR) between 60 
and 85. This indicates that overall respondents felt their health to be good, although several outliers 
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indicated they were experiencing very poor health. There were also significant differences in 
reported EQ5D scores between centres (p=.038). 
Univariate regression was used to explore associations of EQ5D against each of the problem items 
(ranked: none/ mild/ moderate/ severe). Regression co-efficients indicate a negative correlation 
exists between severity of problems and reported HRQoL, with the effect being monotonic for most 
problems, i.e., the worse a problem was experienced, the lower the reported HRQoL (table 4).  All 
problems were significantly associated with lower HRQoL, at least at some level of severity (mild/ 
moderate/ severe) when compared to absence of the problem, with the exception of ‘losing your 
hair’. The strongest effect sizes existed for ‘difficulty managing everyday tasks or work’ when 
experienced as severe (B=-.472), followed by ‘low in mood’ (B=-.288) and ‘unable to concentrate, 
forgetful or confused' (B=.265), or when ‘difficulties in relationships with family or friends’ was 
experienced as moderate (B=-229). Notably, while being ‘tired, fatigued or lacked energy’ was the 
most prevalent problem reported by 90% of respondents, its impact on HRQoL when experienced as 
mild (B=-0.074) or moderate B=-0.0143) was lower than that for relationship difficulties (mild; -0.113; 
moderate: -0.229). The impact of nausea and vomiting were lower still.     
Results from multivariate linear regression suggested that when all problem items were included 
within a model, few had a consistent predictive relationship with HRQoL. The largest and most 
consistent effect size was for experiencing ‘difficulty managing everyday tasks’, and impact on 
HRQoL was found significant at any degree of reported severity (mild: B=-0.058,p=.027; moderate: 
B=-0.120, p=.001; severe: B=0.355, p<.001). The second largest effect size was for ‘difficulties with 
relationships with friends and family’, (B=-0.137, p=.199) and thirdly, ‘pain/irritation at injection site’ 
(B=-0.116, p=.121), when both are experienced as severe. This may in part be explained by the 
broadness of the item ‘difficulty managing everyday tasks’, which may incorporate impact from 
several of the other more narrowly defined items, i.e. ‘feeling anxious’, ‘low in mood’ and ‘financial 
issues’.  
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Variation in supportive care for problems 
Table 2 shows whether respondents received supportive care (always/usually/occasionally/never) 
for physical/psychological problems and social/emotional problems. There were clear differences in 
the supportive care provided for these two types of chemotherapy-associated problem, and large 
and statistically significant variations were found to exist between centres in almost all the reported 
aspects of support. Regarding physical and psychological problems, 70.7% (n=252) of respondents 
reported staff ‘always’ ask them about their problems, with a range between centres of 47.2% and 
90.2%. Responses to the other questions in this section found that: 63.9% (n=225) of respondents 
reported staff were ‘always’ aware of their problems (range between centres: 43.3%-83.3%); 69.0% 
(n=352) reported staff ‘always’ provided useful information (range: 51.0%-83.6%); 68.8% (n=241) 
reported staff ‘always’ provided practical support (range: 50.2%-84.2%), and; 57.8% (n=207) 
reported they ‘always’ felt confident in their ability to manage the physical and psychological 
symptoms they were experiencing (range: 50.6%-57.8%).   
The responses to questions asked about social and emotional problems indicated far lower levels of 
supportive care, and again significant variations were found between centres. Only 23.5% (n=82) 
respondents reported staff ask them about social and emotional problems (range between sites: 
13.0%-36.6%); 30.6% (n=101) reported staff were ‘always’ aware of their problems (range of 13.6% - 
40.2%); 32.8% (n=109) reported staff ‘always’ provided useful information (range: 22.7%-44.2%); 
34.0% (n=113) reported staff ‘always’ provided practical support (range: 27.2%-43.4%, p=<.001), and; 
47.2% (n=162) reported they were ‘always’ confident in their ability to manage social and emotional 
problems they were experiencing.   
Respondents were asked three general questions regarding the preparation they had received for 
managing their own problems. For each of these questions the majority of respondents reported 
they were prepared and there were no significant differences found between centres: 88.9% (n=313) 
of respondents reported they were ‘always’ confident in knowing who to contact or what to do if 
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they experienced any of the listed problems (χ2(15)=18.322, p=.246, range between centres: 81.4%-
95.8%); 86% (n=306) reported they were ‘always’ confident they knew what problems would require 
them to take emergency action (χ2(15)=9.788, p=.833, range 80.3%-90.4%), and; 85% (n=304) 
reported they had been given the information they needed to prepare them before they started 
their treatment (χ2(15)=20.543, p=.152, range: 76.7%-94.5%). 
Univariate regression was used to explore associations between specific problem items (whether 
experienced moderately or severely) and aspects of supportive care (whether experienced usually or 
always) (Table 5). In many instances, fewer respondents experienced particular problems either 
moderately/ severely when they received appropriate supportive care ‘usually or always’ than those 
who received supportive care only ‘occasionally or never’.  For example, 46% (n=145) of respondents 
who reported they always or usually received ‘useful practical support’ from staff to help manage 
problems experienced severe or moderate ‘tiredness, fatigued or lacked energy’, compared with 69% 
(n=20) of those who only occasionally or never received such support. Associations between 
supportive care and problems were significant for six problem items, including all three categorised 
as social and emotional (‘tired, fatigued or lacked energy’; ‘trouble sleeping’; ‘pain or irritation at 
injection site’; ‘diarrhoea’; ‘difficulty managing everyday tasks’; and ‘difficulties in relationships with 
family or friends’), with increased supportive care related to decreased problem severity. This 
finding indicates that for these problems at least, quality supportive care may make an important 
difference to the HRQoL of patients.  
DISCUSSION 
This study identified 17 of the most prevalent and severe chemotherapy-associated problems facing 
individuals undergoing chemotherapy for cancer. A survey incorporating these problem items found 
the most frequently reported were tiredness/fatigue, problems with taste and smell and problems 
completing everyday tasks or work. Overall, response rate was comparable with the primary care 
postal survey[31], but varied widely between centres partly due to sickness of individual staff 
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members responsible for questionnaire administration. While significant variations also existed 
between centres in terms of gender and tumour site, these variables were controlled for in analysis.  
All included problem items were found to be independently predictive of decreased HRQoL, and 
almost all of them had significant association with HRQoL. When combined in a multivariate model 
the item ‘difficulty with everyday tasks and work’ had the largest and most consistent effect size and 
was the only item that had a significant association with HRQoL. While this finding might suggest this 
one item to be the most useful of the problems for identifying the impact of chemotherapy on 
patients, it would not be a sufficient measure by itself given that it was neither the most prevalent 
problem item, nor the most severe when experienced.  
Emotional and social problems were found to be as prevalent amongst survey participants as some 
physical and psychological symptoms. Moreover, difficulties with relationships (the least prevalent 
problem amongst this participant group) were found to have a much stronger effect on HRQoL when 
experienced as mild or moderate than tiredness/fatigue (most prevalent problem). An emerging 
shift from concerns about physical side-effects to psychosocial issues was identified almost two 
decades ago[32], and more recently Carelle et al.[3] found the most troubling problem faced by 
patients to be psychological. Our scoping review also found issues such as difficulties with 
relationships and worries concerning finances were bothersome for some individuals despite their 
relevance rarely being reported in the literature[8]. This may be because while effective 
interventions and drugs are widely available to address treatment toxicities, support interventions 
for emotional and social issues have not been as well developed. The fact that research to date has 
given little attention to the prevalence of these concerns is likely due to multiple reasons, but may 
partly stem from a perception that these are not significant problems for patients. This study 
indicates that contrary to this perception, psycho-social issues experienced by people receiving 
chemotherapy can significantly impact upon their HRQoL.  
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The survey included questions requesting patients to report the quality of supportive care they had 
received from staff for their chemotherapy-associated problems. Findings indicate that those 
patients always or usually receiving supportive care for problems experienced them as less severe, 
sometimes significantly less, than those who never or rarely received supportive care. The study also 
found that while very few respondents reported that they never received supportive care for 
physical and psychological problems, over a fifth reported they never received such support for 
social and emotional problems. This finding indicates health professionals prioritise physical and 
psychological problems, and attribute less importance to social and emotional problems. Effective 
communication between clinicians, patients and their families is an essential part of supportive care, 
and reduces anxiety and depression and promotes emotional functioning, HRQoL and improved 
outcomes[34,35]. Nevertheless, as previous evidence has also shown, problems faced by cancer 
patients are frequently undetected by health care professionals[18,36, 37], and patients often 
remain unable to manage their symptoms through a lack of information and communication with 
health professionals[38].  
Significant variations in symptom prevalence and supportive care received were reported between 
collaborating cancer centres, which may be partly due to differences in patient expectations, socio-
demographic characteristics, and tumour and treatment types. Variations may also be associated 
with different levels of training and the skill-mix of staff within different units, organisational 
characteristics including leadership and the coordination of care[30,39,40]. Chemotherapy-
associated problems are experienced subjectively by patients[41,42], and different problems will be 
associated with different chemotherapy regimens[43,44]. Moreover, reports of the problems cancer 
patients perceive most bothersome change from one decade to the next[33], which may be due to 
advances in chemotherapy and associated supportive treatments. If providers were aware of the 
prevalence with which the most common treatment-related problems were experienced by patients 
receiving chemotherapy in their unit, then service changes might be facilitated to address the 
related supportive care needs. 
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Given the prevalence and impact of these problem items on HRQoL, the mitigating effect of 
supportive care, and the variations found to exist between centres, a mechanism for assessing 
quality of care in ambulatory cancer units might facilitate service improvements. Given our findings, 
any PROM/ PREM developed for this purpose would need to include all 17 problems identified by 
this study if the full potential impact of chemotherapy on patients was to be adequately reflected. 
The future research implications in this area are to determine the extent to which service providers 
are aware of these problems and their impact, and whether routine use of a PROM/PREM based on 
these items to monitor care quality could effectively target improvements to supportive care.  
Limitations of the study 
Administration of questionnaires was delegated to collaborators within each centre, but while 
response rate was low at one centre (20%) it was 57% or higher in all other centres. Our convenience 
sample may not be entirely representative of the population of chemotherapy patients (nor centres), 
and some bias may exist as respondents were self-selecting. Nevertheless, the high prevalence of 
problems amongst participants is unlikely to be purely a selection effect, and problem prevalence 
might indeed be higher than reported. Despite positive associations between respondents 
reportedly receiving greater supportive care and experiencing problems less severely, no causal 
direction of these associations can be claimed. Finally, disease progression may negatively impact 
upon symptom prevalence, but as data on patient performance status were not collected in this 
study, we cannot account for its possible impact on our results.   
CONCLUSION  
For patients receiving cancer chemotherapy, we have identified the most prevalent problems and 
those that have most impact on HRQoL. Some of these problems, particularly emotional and social 
problems, have rarely been reported in previous studies. We provide evidence that supportive care 
may mitigate problems and improve HRQoL, but that it is more often provided for physical and 
15 
 
psychological problems than emotional and social problems. Variations exist between centres both 
in problem prevalence and perceptions of supportive care received. While these differences may or 
may not be related to the quality of services provided, they clearly indicate the need for services to 
consider the specific supportive care needs of their patient populations when planning provision. 
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Table 1: prevalence and severity of chemotherapy associated problems  
Rank Problem Prevalence1 Severity Association with 
centres Severe 
problem 
Moderate  
problem 
Mild 
problem 
No 
problems 
1 Tired, fatigued or lacked energy 90% 11% 37% 42% 10% x2(15) = 29.300, p=.015b 
2 Changes to your sense of taste or smell 69% 11% 24% 34% 31% x2(15) = 15.405, p=.423 
3 Difficulty managing everyday tasks or work 61% 4% 19% 38% 40% x2(15) = 10.976, p=.754  
4 Trouble sleeping 59% 9% 21% 29% 41% x2(15) = 30.600, p=.010b 
5 Constipation 59% 9% 20% 30% 41% x2(15) =22.102, p=.105 
6 Low in mood 56% 4% 16% 36% 43% x2(15 )=36.138, p=.006b 
7 Feeling sick (nauseous/queasy) 56% 7% 15% 34% 44% x2(15) =26.681, p=.031b 
8 Feeling anxious 54% 5% 16% 33% 46% x2(15) = 14.631, p=.478 
9 Lost appetite/lost interest in food 54% 5% 17% 32% 46% x2(15) = 15.319, p=.429 
10 Unable to concentrate, forgetful or confused 52% 3% 11% 38% 48% x2(15) = 11.525, p=715 
11 Losing your hair  47% 13% 14% 20% 54% x2(15) =32.213, p=.006b 
12 Sore mouth or tongue 46% 6% 12% 28% 54% x2(15) = 21.364, p=.126 
13 Diarrhoea 39% 4% 12% 23% 61% x2(15) = 25.667, p=.042b 
14 Sickness (vomiting) 35% 4% 10% 21% 65% x2(15) = 20.660, p=.148 
15 Financial worries 31% 4% 11% 16% 68% x2(15) = 26.680, p=.031b 
16 Pain or irritation at your injection / infusion (needle) site 30% 2% 8% 20% 70% x2(15) = 14.728, p=.471 
17 Difficulties in relationships with family or friends 19% 1% 5% 13% 81% x2(15) = 5.285, p=989 
Note: a Prevalence for each item is calculated by combining figures for participants who reported experiencing them as mild, moderate or severe;  
b p-Value statistically significant (p<.050) 
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Table 2: Survey responses to supportive care questions 
Problem type Frequency Association with 
centre   Always Usually Occasionally Never 
Physical and psychological 
symptoms 
    (Chi2) 
Do you get asked about your 
symptoms? 
70.8% (252) 19.4% (69)  7.3% (26) 2.5% (9) x2(15) =64.744, 
p=<.001a  
 
Are all the staff who need to 
know aware of your 
symptoms? 
63.9% (225) 29.5% (104) 4.5% (16) 1.9% (7) x2(15)=42.857, 
p=.002a 
Do staff provide useful 
information to help you 
manage your symptoms? 
69.0% (243) 23.3% (82) 6.8% (24) 0.9% (3) x2(15) = 53.996, 
p=<.001a 
Do staff provide useful practical 
support to help your 
symptoms? 
68.9% (241) 22.6% (79) 5.7% (20) 2.9% (10) x2(15)=42.086, 
p=.011a 
Do you feel confident in your 
ability to manage the 
symptoms you are 
experiencing? 
57.8% (207) 37.7% (135) 4.2% (15) 0.3% (1) x2(15)=17.705, 
p=.279 
Social and emotional problems      
Do you get asked about social, 
emotional or other problems? 
23.6% (82) 25.0% (87) 26.7% (93 24.7% (86) x2(15)=46.093, 
p=<.001a 
 
Are all the staff who need to 
know aware of social, 
emotional or other 
problems? 
30.7% (101) 27.1% (89) 21.6% (71) 20.7% (68) x2(15)=36.456, 
p=.002a 
Do staff provide useful 
information to help you 
manage social, emotional or 
other problems? 
32.8% (109)  28.6% (95) 17.5% (58) 21.1% (70) x2(15) = 40.514, 
p=<.001a 
Do staff provide useful practical 
support to help your social, 
emotional or other problems? 
34.0% (113) 28.6% (95) 15.4% (51) 22.0% (73) x2(15 =30.298, 
p=.011a 
Do you feel confident in your 
ability to manage the social, 
emotional or other problems 
you are experiencing? 
47.2% (162) 36.4% (125) 10.8% (37) 5.5% (19)  x2(15)=23.241, 
p=.079 
General support      
Are you confident that you 
know who to contact / what to 
do if you have such problems 
88.9% (313) 9.1% (32) 1.4% (5) 0.6% (2) x2(15)=18.322, 
p=.246 
Are you confident that you 
know what problems would 
require you to take 
emergency action? 
86.0% (306) 11.8% (42) 1.7% (6) 0.6% (2) x2(15)=9.788, 
p=.833 
Did you get the information 
you needed to prepare you 
before you started your 
course of treatment? 
84.7% (304) 13.4% (48) 1.7% (6) 0.3% (1) x2(15)=20.543, 
p=.152 
Note: a p value statistically significant (p<.050). 
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Table 3: Site, demographic and treatment characteristics (n=363) 
 Characteristic N= % Association with 
centres 
Chemotherapy 
centre 
Site 1 24 20  
Site 2 68 57 
Site 3 75 63 
Site 4 50a 78 
Site 5 73 61 
Site 6 73 61 
Gender Male 127 35.0 χ2(5) = 17.2 
p=.004b Female 197 54.3 
Missing 39 10.7 
Age 18-30 years 2 0.6 χ2(25)=23.2,  
p=..562 31-40 years 14 3.9 
41-50 years 50 13.9 
51-60 years 99 27.5 
61-70 years 100 27.8 
70 years plus 95 26.4 
Tumour site Bladder/urological 11 3.1 χ2(60) = 138.2 
p=<.001b Leukaemia 11 3.1 
Bowel 62 17.1 
Breast 89 24.8 
Gynaecological 35 9.7 
Head & neck 5 1.4 
Lung 42 11.7 
Lymphoma 24 6.7 
Oesophagus 18 5.0 
Prostate  9 2.5 
Stomach  10 2.8 
Other 28 7.8 
Chemo cycle Not started 3 0.9 χ2(40) = 43.4 
p=.327 1 15 4.3 
2 57 16.3 
3 61 17.4 
4 48 13.7 
5 43 12.3 
6 32 9.1 
7 63 18.0 
Finished treatment 28 8.0 
Note: a Site 4 only administered 64 questionnaires while all other sites administered 120; 
b  p-Value statistically significant (p<.050)  
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Table 4: Problem-by-problem univariate analysis and multivariate full model (controlled for centre, age and gender) 
Problem Severity  Univariable Model Multivariable Model 
  95% CI   95% CI  
 B Lower Upper p-value B Lower Upper p-value 
Difficulty managing everyday tasks or work Mild  -0.131 -0.177 -0.085 <0.0005a -0.058 -0.109 -0.006 0.027a 
Moderate -0.216 -0.271 -0.161 <0.0005a -0.120 -0.188 -0.052 0.001a 
Severe  -0.472 -0.589 -0.355 <0.0005a -0.355 -0.512 -0.199 0.000a 
Feeling anxious  Mild  -0.107 -0.157 -0.058 <0.0005a -0.018 -0.074 -0.037 0.521 
Moderate  -0.162 -0.224 -0.100 <0.0005a -0.056 -0.133 -0.021 0.154 
Severe  -0.190 -0.296 -0.083 0.001a 0.069 -0.076 -0.213 0.349 
Low in mood Mild  -0.100 -0.150 -0.051 <0.0005a -0.022 -0.077 -0.034 0.436 
Moderate  -0.139 -0.203 -0.075 <0.0005a -0.018 -0.099 -0.063 0.662 
Severe  -0.288 -0.403 -0.173 <0.0005a -0.020 -0.202 -0.162 0.827 
Unable to concentrate, forgetful or confused Mild  -0.128 -0.173 -0.082 <0.0005a -0.084 -0.136 -0.033 0.001a 
Moderate  -0.126 -0.196 -0.057 <0.0005a -0.032 -0.106 -0.042 0.396 
Severe  -0.265 -0.402 -0.128 <0.0005a -0.046 -0.206 -0.115 0.577 
Difficulties in relationships with family or friends Mild  -0.113 -0.181 -0.045 0.001a 0.003 -0.067 0.073 0.930 
Moderate  -0.229 -0.324 -0.135 <0.0005a -0.081 -0.183 0.021 0.118 
Severe  -0.170 -0.340 -0.001 0.049a -0.137 -0.345 0.072 0.199 
Tired, fatigued or lacked energy Mild  -0.074 -0.150 0.002 0.058 -0.047 -0.124 0.031 0.237 
Moderate  -0.143 -0.220 -0.066 <0.0005a -0.061 -0.147 0.025 0.164 
Severe  -0.223 -0.318 -0.128 <0.0005a -0.098 -0.210 0.015 0.089 
Feeling sick (nauseous/queasy) Mild  -0.069 -0.121 -0.017 0.010a -0.024 -0.033 -0.081 0.403 
Moderate  -0.119 -0.184 -0.053 <0.0005a -0.017 -0.058 -0.092 0.653 
Severe  -0.163 -0.261 -0.065 0.001a -0.100 -0.029 -0.228 0.127 
Constipation  Mild -0.041 -0.096 0.013 0.136 -0.010 -0.062 -0.042 0.719 
Moderate -0.095 -0.158 -0.032 0.003a -0.026 -0.087 -0.036 0.415 
Severe -0.159 -0.242 -0.076 <0.0005a -0.056 -0.142 -0.030 0.202 
Sickness (vomiting) Mild  -0.099 -0.157 -0.041 0.001a -0.036 -0.100 -0.029 0.278 
Moderate  -0.142 -0.217 -0.067 <0.0005a -0.041 -0.125 -0.042 0.332 
Severe -0.073 -0.203 -0.057 0.272 -0.088 -0.257 -0.081 0.304 
Financial worries Mild  -0.099 -0.164 -0.034 0.003a -0.055 -0.116 0.006 0.077 
Moderate  -0.089 -0.163 -0.015 0.018a -0.025 -0.097 0.047 0.490 
Severe -0.136 -0.247 -0.026 0.016a -0.017 -0.125 0.092 0.764 
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Trouble sleeping  Mild  0.006 -0.048 0.061 0.817 -0.018 -0.068 0.033 0.492 
Moderate -0.097 -0.158 -0.036 0.002a -0.049 -0.107 0.008 0.093 
Severe  -0.125 -0.209 -0.041 0.004a -0.007 -0.099 0.084 0.877 
Lost appetite/lost interest in food Mild  -0.020 -0.071 0.032 0.449 0.016 -0.035 0.067 0.542 
Moderate  -0.105 -0.170 -0.041 0.001a -0.030 -0.100 0.041 0.403 
Severe -0.150 -0.252 -0.048 0.004a 0.006 -0.108 0.120 0.914 
Diarrhoea  Mild  -0.039 -0.095 0.017 0.173 -0.028 -0.081 0.026 0.309 
Moderate -0.064 -0.136 0.008 0.079 -0.004 -0.078 0.071 0.918 
Severe -0.181 -0.296 -0.065 0.002a -0.003 -0.126 0.119 0.958 
Changes to your sense of taste or smell Mild -0.002 -0.058 0.054 -0.935 -0.020 -0.034 0.074 0.466 
Moderate  -0.030 -0.092 0.032 -0.345 -0.031 -0.030 0.093 0.315 
Severe -0.135 -0.216 0.054 0.001a -0.005 -0.100 0.090 0.916 
Sore mouth or tongue Mild -0.015 -0.068 -0.039 0.585 -0.021 -0.030 0.072 0.414 
Moderate -0.049 -0.123 -0.024 0.189 -0.042 -0.030 0.115 0.252 
Severe -0.140 -0.239 -0.041 0.006a -0.019 -0.120 0.082 0.711 
Pain or irritation at your injection / infusion (needle) site Mild  -0.014 -0.044 0.071 0.644 0.020 -0.034 -0.074 0.472 
Moderate -0.062 -0.149 0.024 0.159 0.043 -0.044 0.130 0.329 
Severe  -0.225 -0.373 -0.078 0.003a -0.116 -0.264 -0.031 0.121 
Losing your hair Mild 0.027 -0.036 0.091 0.394 0.039 -0.019 0.097 0.186 
Moderate -0.001 -0.072 0.070 0.968 -0.012 -0.080 0.055 0.720 
Severe  -0.072 -0.145 0.002 0.055 0.031 -0.043 0.106 0.405 
Note a p value statistically significant (p<.050). 
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Table 5: Associations between chemotherapy-associated problems and supportive care provided.  
Problem Type (experienced either moderately or 
severely) 
Do you get asked about your symptoms? Are all the staff aware who need to know 
aware of your symptoms? 
Do staff provide useful information to 
help you manage your problems? 
Do staff provide useful practical support 
to help your problems? 
 
Physical/psychological  
Always/ 
usually 
% (n=) 
Occasionally/ 
never 
% (n=) 
 
(Chi2) 
p= 
Always/ 
usually 
% (n=) 
Occasionally/ 
never 
% (n=) 
 
(Chi2) 
p= 
Always/ usually 
% (n=) 
Occasionally
/ never 
% (n=) 
 
(Chi2) 
p= 
Always/ 
usually 
% (n=) 
Occasionally/ 
never 
% (n=) 
 
(Chi2) 
p= 
Tired, fatigued or lacked energy 
 
47.0% (148) 65.7% (23) .035a 47.7% (155) 66.7% (14) .092 46.9% (150) 69.2% (18) .023a 46.0% (145) 69.0% (20) .015a 
Changes to your sense of taste or smell 
 
34.3% (106) 37.1% (13) .436 34.0 (108) 36.4% (8) .818 33.7% (106) 42.3% (11) .246 33.2% (103) 46.4% (13) .116 
Trouble sleeping 
 
28.9% (90) 40.0% (14) .176 27.3% (87) 65.2% (15) .000a 28.2% (89) 51.9 (14) .010a 27.3% (85) 53.3% (16) .003a 
Constipation 
 
28.4 (89) 37.1% (13) .283 28.3% (91) 45.5% (10) .087 28.3% (90) 38.5% (10) .273 28.3% (89) 32.1% (9) .662 
Low in mood 
 
19.7% (61) 29.4% (10) .183 20.5% (65) 17.4% (4) .720 20.4% (64) 22.2% (6) .495 19.3% (60) 28.6% (8) .175 
Feeling sick (nauseous/queasy) 
 
22.3% (69) 15.2% (5) .345 22.6% (72) 9.5% (2) .159 22.2% (70) 16.0% (4) .330 21.5% (67) 17.9% (5) .430 
Feeling anxious 
 
21.6% (67) 22.9% (8) .866 21.6% (69) 22.7% (5) .904 22.5% (71) 15.4% (4) .286 21.1% (66) 28.6% (8) .242 
Lost appetite/ lost interest in food 
 
88.5 (69) 11.5 (9) .345 21.6% (69) 39.1% (9) .052 87.2 (68) 12.8 (10) .058 88.0 (66) 12.0 (9) .185 
Unable to concentration, forgetful or confused 
 
13.4% (41) 14.7% (5) .838 12.8% (40) 18.2% (4) .468 13.5% (42) 11.5% (3) .530 13.0% (40) 21.4% (6) .167 
Losing your hair 
 
27.9% (85) 17.6%  (6) .202 27.5% (86) 18.2% (4) .342 27.1% (84) 26.9% (7) .985 27.0% (83) 20.7% (6) .459 
Sore mouth or tongue 
 
18.4% (57) 17.6% (6) .909 18.0% (57) 2.7% (5) .578 18.5% (58) 19.2% (5) .547 17.7% (55) 21.4% (6) .390 
Diarrhoea 
 
15.6% (48) 17.6% (6) .754 14.5% (46) 33.3% (7) .022a 15.7% (49) 16.0% (4) .573 14.8% (46) 22.2% (6) .222 
Sickness (vomiting) 
 
14.4% (44) 8.8% (3) .370 13.5% (42) 21.7% (5) .207 12.9% (40) 25.9% (7) .065 13.4% (41) 20.7% (6) .204 
Pain or irritation at your injection/ infusion site 
 
9.1% (28) 18..2% (6) .098 8.9% (28) 27.3% (6) .006a 8.9% (28) 19.2% (5) .089 8.7% (27) 22.2% (6) .023a 
Social/ emotional 
 
            
Financial worries 
 
16.1% (26) 15.0% (26) .006a 14.4% (26) 17.6% (24) .261 14.9% (29) 17.7% (22) .298 14.6% (29) 18.3% (22) .232 
Difficulty managing everyday tasks 
 
19.8% (32) 24.6% (43) .288 18.7% (34) 28.3% (39) .030a 18.4% (36) 30.2% (38) .011a 18.5% (37) 30.3% (37) .011a 
Difficulties in relationships with family or friends 
 
6.7% (11) 6.4% (11) .908 5.5% (10) 8.9% (12) .167 5.5% (17) 22.2% (6) 
 
.001a 5.2% (16) 24.1% (7) .000a 
Note: a p value statistically significant (p<.050).  
